Hyaluronates

Prior Authorization Request

Your patient's benefit plan requires prior authorization for certain medications. In order to make appropriate medical necessity determinations, your patient's diagnosis and other clinical information is required. **Please complete the information requested on the form below and fax this form to Priority Partners, toll-free at 1-866-212-4756** to initiate the review process. If you have questions regarding the prior authorization please contact Priority Partners at 888-819-1043 Option 4**.**

Patient's Name: _____ **Date**: _____
Patient's ID: _____ **Patient's Date of Birth:** _____
Physician's Name: _____
Specialty: _____ **NPI#:** _____
Physician Office Telephone: _____ **Physician Office Fax:** _____

Referring Provider Info: ❑ Same as Requesting Provider
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Rendering Provider Info: ❑ Same as Referring Provider ❑ Same as Requesting Provider
Name: _____ **NPI#:** _____
Fax: _____ **Phone:** _____

Approvals may be subject to dosing limits in accordance with FDA-approved labeling, accepted compendia, and/or evidence-based practice guidelines.

Required Demographic Information:

Patient Weight: _____*kg*

Patient Height: _____*cm*

Please indicate the place of service for the requested drug:

❑ *Ambulatory Surgical* ❑ *Home* ❑ *Off Campus Outpatient Hospital*
❑ *On Campus Outpatient Hospital* ❑ *Office*

Drug Information:

Strength/Measure _____ *Units* ❑ ml ❑ Gm ❑ mg ❑ ea ❑ Un

Directions(sig) _____ *Route of administration* _____

Dosing frequency _____

Send completed form to: Priority Partners Fax: 1-866-212-4756

 JHHC SOC Hyaluronates SGM 1765 A - 07.2023.

Site of Service Questions:

A. Indicate the site of service requested:
- ❑ On Campus Outpatient Hospital
- ❑ Off Campus Outpatient Hospital
- ❑ Home based setting, *skip to Criteria Questions*
- ❑ Community office, *skip to Criteria Questions*
- ❑ Ambulatory infusion site, *skip to Criteria Questions*

B. Is the patient less than 18 years of age?
- ❑ Yes, *skip to Clinical Criteria Questions*
- ❑ No

C. Has the patient experienced an adverse event with the requested product that has not responded to conventional interventions (eg acetaminophen, steroids, diphenhydramine, fluids, other pre- medications or slowing of infusion rate) or a severe adverse event (anaphylaxis, anaphylactoid reactions, myocardial infarction, thromboembolism, or seizures) during or immediately after an infusion? ***ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.*** ❑ Yes, *skip to Clinical Criteria Questions* ❑ No

D. Is the patient medically unstable which may include respiratory, cardiovascular, or renal conditions that may limit the member's ability to tolerate a large volume or load or predispose the member to a severe adverse event that cannot be managed in an alternate setting without appropriate medical personnel and equipment? ***ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.***
❑ Yes, *skip to Clinical Criteria Questions* ❑ No

E. Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting? ***ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.***
❑ Yes, *skip to Clinical Criteria Questions* ❑ No

F. Does the patient have significant behavioral issues and/or physical or cognitive impairment that would impact the safety of the infusion therapy AND the patient does not have access to a caregiver? ***ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.***
❑ Yes, *skip to Clinical Criteria Questions* ❑ No

G. Has the patient's home been deemed not eligible or appropriate for home infusion services by a home infusion provider? ***ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.***
❑ Yes, *skip to Clinical Criteria Questions* ❑ No

H. Does the patient have severe venous access issues that require the use of special interventions only available in the outpatient hospital setting? ***ACTION REQUIRED: If 'Yes', please attach supporting clinical documentation.***
❑ Yes ❑ No

Clinical Criteria Questions:

What is the ICD-10 code? _____

1. What is the prescribed medication?

❒ Gel-One, *Continue to 2*

❒ Gelsyn-3, *Continue to 2*

❒ Supartz FX, *Continue to 2*

❒ Visco-3, *Continue to 2*

❒ Durolane, *Continue to 2*

❒ Euflexxa, *Continue to 2*

Send completed form to: Priority Partners Fax: 1-866-212-4756

❒ GenVisc 850, *Continue to 2*

❒ Hyalgan, *Continue to 2*

❒ Hymovis, *Continue to 2*

❒ Monovisc, *Continue to 2*

❒ Orthovisc, *Continue to 2*

❒ Synojoynt, *Continue to 2*

❒ Synvisc, *Continue to 2*

❒ Synvisc One, *Continue to 2*

❒ TriVisc, *Continue to 2*

❒ Triluron, *Continue to 2*

❒ 1% sodium hyaluronate, *Continue to 2*

2. What is the diagnosis?

❒ Osteoarthritis of the knee, *Continue to 3*

❒ Other, please specify. _____, *Continue to 3*

3. Is the diagnosis supported by radiographic evidence of osteoarthritis of the knee, such as joint space narrowing, subchondral sclerosis, osteophytes, and sub-chondral cysts?

❒ Yes, *Continue to 5*

❒ No, *Continue to 4*

4. At the time of diagnosis, did/does the patient have at least 5 of the following signs and symptoms: A) Bony enlargement, B) Bony tenderness, C) Crepitus (noisy, grating sound) on active motion, D) Erythrocyte sedimentation rate (ESR) less than 40 mm per hour, E) Less than 30 minutes of morning stiffness, F) No palpable warmth of synovium, G) Over 50 years of age, H) Rheumatoid factor less than 1:40 titer (agglutination method), or I) Synovial fluid signs (clear fluid of normal viscosity and WBC less than 2000/mm3)?

❒ Yes, *Continue to 5*

❒ No, *Continue to 5*

5. Does the patient have knee pain which interferes with functional activities (e.g., ambulation, prolonged standing)?

❒ Yes, *Continue to 6*

❒ No, *Continue to 6*

6. Has the patient experienced an inadequate response or adverse effects with non-pharmacologic treatment options (e.g., physical therapy, regular exercise, insoles, knee bracing, weight reduction)?

❒ Yes, *Continue to 7*

❒ No, *Continue to 7*

7. Has the patient experienced an inadequate response or intolerance to a trial of an analgesic (e.g., acetaminophen up to 3 to 4 grams per day, non-steroidal anti-inflammatory drugs [NSAIDs], topical capsaicin cream) for at least 3 months?

❒ Yes, *Continue to 9*

❒ No, *Continue to 8*

8. Does the patient have a contraindication to a trial of an analgesic (e.g., acetaminophen up to 3 to 4 grams per day, non-steroidal anti-inflammatory drugs [NSAIDs], topical capsaicin cream) for at least 3 months?
❒ Yes, *Continue to 9*
❒ No, *Continue to 9*

9. Has the patient experienced an inadequate response or intolerance to a trial of intraarticular steroid injections for at least 3 months?
❒ Yes, *Continue to 11*
❒ No, *Continue to 10*

10. Does the patient have a contraindication to a trial of intraarticular steroid injections for at least 3 months?
❒ Yes, *Continue to 11*
❒ No, *Continue to 11*

11. Is the patient scheduled to undergo a total knee replacement within 6 months of starting treatment?
❒ Yes, *Continue to 12*
❒ No, *Continue to 12*

12. Please indicate if this request is for initiation of therapy (first time use), continuation of therapy (in the middle of a treatment series), or re-start of therapy (the patient has been treated with a viscosupplementation in the past).
❒ Initiation of therapy (first time use), *No further questions*
❒ Continuation of therapy (the patient is in the middle of therapy), *No further questions*
❒ Re-start of therapy (the patient has received a viscosupplementation in the past), *Continue to 13*

13. Has the patient experienced improvement in pain and functional capacity following the previous injections?
❒ Yes, *Continue to 14*
❒ No, *Continue to 14*

14. Was the previous series of injections completed at least 6 months prior to this request?
❒ Yes, *No Further Questions*
❒ No, *No Further Questions*

I attest that this information is accurate and true, and that documentation supporting this information is available for review if requested by Priority Partners.

X_____
Prescriber or Authorized Signature **Date (mm/dd/yy)**

Send completed form to: Priority Partners Fax: 1-866-212-4756

Priority Partners ● 7231 Parkway Drive Suite 100 ● Hanover, MD 21076
Phone: 888-819-1043 ● Fax: 1-866-212-4756 ● www.jhhc.com